NCT07213609View on ClinicalTrials.gov

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

September 28, 2028

Study Completion Date

October 27, 2028

Conditions
Neoplasms, Colorectal
Interventions
DRUG

GSK5460025

GSK5460025 will be administered

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT07213609 - A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | Biotech Hunter | Biotech Hunter